Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | CFD | P00746 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 6/20 | 0.39 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452598 | 0.93 | PRPS1 (0.43) | KCNH2OPRK1CFDHTR3APRPS1 | |
| SCHEMBL5459672 | 0.91 | KCNH2 (0.42) | KCNH2OPRK1CFDHTR3APRPS1 | |
| SCHEMBL5453047 | 0.90 | PRPS1 (0.41) | KCNH2OPRK1CFDHTR3APRPS1 | |
| SCHEMBL16316943 | 0.89 | CFD (0.37) | CFDPRPS1CNR2KMT2ASMN1; SMN2 | |
| SCHEMBL5444195 | 0.88 | KCNH2 (0.39) | KCNH2OPRK1CFDHTR3APRPS1 | |
| SCHEMBL5449100 | 0.85 | CNR2 (0.41) | KCNH2OPRK1HTR3ACNR2KMT2A | |
| SCHEMBL14410949 | 0.84 | HTR3A (0.52) | KCNH2CFDHTR3ACNR2KMT2A | |
| SCHEMBL5453559 | 0.83 | ALDH1A1 (0.50) | KCNH2OPRK1HTR3APRPS1CNR2 | |
| SCHEMBL16316985 | 0.82 | PRPS1 (0.42) | CFDHTR3APRPS1CNR2KMT2A | |
| SCHEMBL5452412 | 0.82 | PRPS1 (0.42) | KCNH2OPRK1CFDHTR3APRPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | KCNH2 4294/4885OPRK1 250/4885CFD 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.